Products Press Releases Partnering Careers Contact

Featured Post

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD

August 29, 2024

June 3, 2021

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

May 4, 2021

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets)

January 5, 2021

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets)

October 28, 2020

KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada

August 26, 2020

KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity

August 18, 2020

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada